Lack of Effect of Methylene Blue in the SOD1 G93A Mouse Model of Amyotrophic Lateral Sclerosis

BACKGROUND: Methylene blue (MB) is a drug with a long history and good safety profile, and with recently-described features desirable in a treatment for ALS. METHODOLOGY/PRINCIPAL FINDINGS: We tested oral MB in inbred high-copy number SOD1 G93A mice, at 25 mg/kg/day beginning at 45 days of age. We measured disease onset, progression, and survival. There was no difference in disease onset between MB-treated mice and controls, although subgroup …